KRRO
Korro Bio, Inc.
NASDAQ · USHealthcareBiotechnology
$11.50-6.12%
Price as of Jul 20, 2026
KRRO profitability
Korro Bio, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 73.2%
- EBITDA margin
- -2034.0%
- EBIT margin
- -2154.0%
- Net margin
- -2954.1%
- Free cash flow margin
- -1837.7%
Returns
- Return on equity
- -94.9%
- Return on assets
- -61.8%
- Return on invested capital
- -50.9%
- Asset turnover
- 0.03x
Cash efficiency
- Cash from operations
- -$70.2M
- Cash per share
- $7.90
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.